» Articles » PMID: 35795059

Blocking ATM Attenuates SKOV3 Cell Proliferation and Migration by Disturbing Expression

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Jul 7
PMID 35795059
Authors
Affiliations
Soon will be listed here.
Abstract

Blocking ataxia telangiectasia mutated (ATM), a crucial player in DNA repair responses, has been proposed as a promising strategy in anti-cancer therapy. Most previous studies have focused on DNA damage response-related pathways after administration of ATM inhibitors. However, ATM inhibition could potentially influence a wide range of changes in gene expression, which remain poorly defined. Here, we report that administration of the ATM inhibitor KU60019 led to impaired migration and enhanced apoptosis in the ovarian cancer cell line SKOV3, accompanied by abnormally elevated O-GlcNAc transferase and O-GlcNAcase expression levels. In addition, KU60019 treatment significantly suppressed expression of in SKOV3 cells. Up-regulation of expression inhibited increases in OGT and OGA level, and reversed the effects of ATM inhibition on apoptosis and migration in SKOV3 cells. Finally, we found aberrant expression of and to be associated with ovarian cancer patient survival. Taken together, our results suggest that ATM inhibition may promote SKOV3 cell apoptosis suppressing and elevating and expression, providing new insights into the application of ATM inhibitors in cancer immunotherapy.

Citing Articles

Therapeutic Potential of Feline Adipose-Derived Stem Cell Exosomes in the Treatment of Feline Idiopathic Cystitis: A Characterization and Functional Analysis of miRNA Content.

Rubini A, Zanotti F, Licastro D, Calogero G, Bettini G, Piccoli C Nanotheranostics. 2025; 9(1):38-51.

PMID: 39744099 PMC: 11667565. DOI: 10.7150/ntno.99383.


O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications.

Xia L, Mei J, Huang M, Bao D, Wang Z, Chen Y Transl Oncol. 2024; 51:102220.

PMID: 39616984 PMC: 11647086. DOI: 10.1016/j.tranon.2024.102220.


Regulation of protein O-GlcNAcylation by circadian, metabolic, and cellular signals.

Liu X, Cai Y, Chiu J J Biol Chem. 2023; 300(2):105616.

PMID: 38159854 PMC: 10810748. DOI: 10.1016/j.jbc.2023.105616.


DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities.

Ovejero-Sanchez M, Gonzalez-Sarmiento R, Herrero A Cancers (Basel). 2023; 15(2).

PMID: 36672401 PMC: 9856346. DOI: 10.3390/cancers15020448.


RYBP Sensitizes Cancer Cells to PARP Inhibitors by Regulating ATM Activity.

Maybee D, Psaras A, Brooks T, Ali M Int J Mol Sci. 2022; 23(19).

PMID: 36233063 PMC: 9570458. DOI: 10.3390/ijms231911764.

References
1.
Choi M, Kipps T, Kurzrock R . ATM Mutations in Cancer: Therapeutic Implications. Mol Cancer Ther. 2016; 15(8):1781-91. DOI: 10.1158/1535-7163.MCT-15-0945. View

2.
Broglio K, Berry D . Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009; 101(23):1642-9. PMC: 4137232. DOI: 10.1093/jnci/djp369. View

3.
Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S . KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 2011; 39(Web Server issue):W316-22. PMC: 3125809. DOI: 10.1093/nar/gkr483. View

4.
Memmott R, Wolfe A, Carbone D, Williams T . Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. J Thorac Oncol. 2021; 16(7):1086-1098. DOI: 10.1016/j.jtho.2021.03.017. View

5.
Xi L, Peng M, Liu S, Liu Y, Wan X, Hou Y . Hypoxia-stimulated ATM activation regulates autophagy-associated exosome release from cancer-associated fibroblasts to promote cancer cell invasion. J Extracell Vesicles. 2021; 10(11):e12146. PMC: 8452512. DOI: 10.1002/jev2.12146. View